Thank you both for being here, and for coming back as well. You've contributed a lot to our studies in the past, and we've had a lot of similar conversations about how we can be competitive in the regulatory environment where we are competing against other partners.
I was looking at testimony from a previous meeting where the CRISPR market was discussed.
I'll direct this first to Ms. Thomas.
You mentioned CRISPR as well, and that this market could be developed quickly, within a year. The Americans are even looking at possibly not going through the same regulatory process for that product, streamlining the process, and then we will have to compete against them.
Would you be able to expand on that at all?